Nanoimmunoengineering Strategies in Cancer Diagnosis and Therapy

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):

Share this content! On (X network) By

Nanoimmunoengineering Strategies in Cancer Diagnosis and Therapy Publisher Pubmed

Ghafelehbashi R^{1, 2} ; Farshbafnadi M^{2, 3} ; Aghdam NS⁴ ; Amiri S^{5, 6} ; Salehi M⁷ ; Razi S^{2, 8, 9}

Show Affiliations

1. Department of Materials and Textile Engineering, College of Engineering, Razi University, Kermanshah, Iran
2. Cancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, Iran
3. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
4. Tabriz University of Medical Sciences, Tabriz, Iran
5. Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
6. Student Research Committee, Pasteur Institute of Iran, Tehran, Iran
7. Student Research Committee, Qazvin University of Medical Sciences, Qazvin, Iran
8. Research Center for Immunodeficiencies, Childrenâ€™s Medical Center, Tehran University of Medical Sciences, Tehran, Iran
9. School of Medicine, Iran University of Medical Sciences, Tehran, Iran

Source: Clinical and Translational Oncology Published:2023

Abstract

Cancer immunotherapy strategies in combination with engineered nanosystems have yielded beneficial results in the treatment of cancer and their application is increasing day by day. The pivotal role of stimuli-responsive nanosystems and nanomedicine-based cancer immunotherapy, as a subsidiary discipline in the field of immunology, cannot be ignored. Today, rapid advances in nanomedicine are used as a platform for exploring new therapeutic applications and modern smart healthcare management strategies. The progress of nanomedicine in cancer treatment has confirmed the findings of immunotherapy in the medical research phase. This study concentrates on approaches connected to the efficacy of nanoimmunoengineering strategies for cancer immunotherapies and their applications. By assessing improved approaches, different aspects of the nanoimmunoengineering strategies for cancer therapies are discussed in this study. © 2022, The Author(s), under exclusive licence to Federacion de Sociedades Espanolas de Oncologia (FESEO).

Related Docs

View other Related Docs

1. Nanoparticles in Cancer Immunotherapies: An Innovative Strategy, Biotechnology Progress (2021)

2. Polymeric Nanoparticles for Dna Vaccine-Based Cancer Immunotherapy: A Review, Biotechnology Letters (2023)

3. Nano-Immunotherapy: Overcoming Delivery Challenge of Immune Checkpoint Therapy, Journal of Nanobiotechnology (2023)

4. Smart Biomaterials to Enhance the Efficiency of Immunotherapy in Glioblastoma: State of the Art and Future Perspectives, Advanced Drug Delivery Reviews (2021)

5. Recent Progress in the Immunotherapy of Hepatocellular Carcinoma: Non-Coding Rna-Based Immunotherapy May Improve the Outcome, Biomedicine and Pharmacotherapy (2023)

6. Cancer Nanomedicine: Special Focus on Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)

7. Advances in Cancer Nanovaccines: A Focus on Colorectal Cancer, Nanomedicine (2025)

8. Nanomedicine for Improvement of Dendritic Cell-Based Cancer Immunotherapy, International Immunopharmacology (2020)

Experts (# of related papers)

View all Related Experts

Nima Rezaei (6)

Hamid Reza Mirzaei (1)

Other Related Docs

9. Resistance to Immunotherapy in Human Malignancies: Mechanisms, Research Progresses, Challenges, and Opportunities, Journal of Cellular Physiology (2022)

10. Targeting Regulatory T Cells by Curcumin: A Potential for Cancer Immunotherapy, Pharmacological Research (2019)

11. In-Vitro and In-Vivo Comparison of Rsag1-Loaded Plga Prepared by Encapsulation and Adsorption Methods As an Efficient Vaccine Against Toxoplasma Gondii”, Journal of Drug Delivery Science and Technology (2020)

12. Understanding the Tumor Microenvironment for Effective Immunotherapy, Medicinal Research Reviews (2021)

13. Emerging Advances of Nanotechnology in Drug and Vaccine Delivery Against Viral Associated Respiratory Infectious Diseases (Varid), International Journal of Molecular Sciences (2021)

14. Recent Advances on Biocompatible and Biodegradable Nanoparticles As Gene Carriers, Expert Opinion on Biological Therapy (2016)

15. Tumor Antigens, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)

16. Tumor Antigens, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)

17. Recent Advances in Regenerative Medicine Strategies for Cancer Treatment, Biomedicine and Pharmacotherapy (2021)

18. Nanomedicine and Advanced Technologies for Burns: Preventing Infection and Facilitating Wound Healing, Advanced Drug Delivery Reviews (2018)

19. Marketed Antiparasitic Nanotechnology-Based Products and Drawbacks, Advances in Antiparasitic Therapies and Drug Delivery (2023)

20. Dna Vaccines As Promising Immuno-Therapeutics Against Cancer: A New Insight, Frontiers in Immunology (2024)

21. Immune Checkpoint Blockade in Melanoma: Advantages, Shortcomings and Emerging Roles of the Nanoparticles, International Immunopharmacology (2022)

22. For and Against Tumor Microenvironment: Nanoparticle-Based Strategies for Active Cancer Therapy, Materials Today Bio (2025)

23. A Concise Review on Cancer Treatment Methods and Delivery Systems, Journal of Drug Delivery Science and Technology (2019)

24. Delivery Systems for Leishmania Vaccine Development, Expert Review of Vaccines (2016)

25. Genetically Modified Immune Cells Targeting Tumor Antigens, Pharmacology and Therapeutics (2020)

26. Nanoparticles and Targeted Drug Delivery in Cancer Therapy, Immunology Letters (2017)

27. Immune Landscape of Hepatocellular Carcinoma: From Dysregulation of the Immune Responses to the Potential Immunotherapies, Cell Biochemistry and Function (2024)

28. Development of Nano-Carriers for Leishmania Vaccine Delivery, Expert Opinion on Drug Delivery (2020)

29. In Vitro Elimination of El4 Cancer Cells From Spermatogonia Stem Cells by Mirna-143- a Nd 206-Loaded Folic Acid-Conjugated Plga Nanoparticles, Nanomedicine (2022)

30. Immunology Meets Bioengineering: Improving the Effectiveness of Glioblastoma Immunotherapy, Cancers (2022)

31. Gas Plasma Irradiation of Breast Cancers Promotes Immunogenicity, Tumor Reduction, and an Abscopal Effect in Vivo, OncoImmunology (2021)

32. Triple-Negative Breast Cancer Treatment Meets Nanoparticles: Current Status and Future Direction, Journal of Drug Delivery Science and Technology (2022)

Style	Citing Format
MLA	Ghafelehbashi R, et al.. "Nanoimmunoengineering Strategies in Cancer Diagnosis and Therapy." Clinical and Translational Oncology, vol. 25, no. 1, 2023, pp. 78-90.
APA	Ghafelehbashi R, Farshbafnadi M, Aghdam NS, Amiri S, Salehi M, Razi S (2023). Nanoimmunoengineering Strategies in Cancer Diagnosis and Therapy. Clinical and Translational Oncology, 25(1), 78-90.
Chicago	Ghafelehbashi R, Farshbafnadi M, Aghdam NS, Amiri S, Salehi M, Razi S. "Nanoimmunoengineering Strategies in Cancer Diagnosis and Therapy." Clinical and Translational Oncology 25, no. 1 (2023): 78-90.
Harvard	Ghafelehbashi R et al. (2023) 'Nanoimmunoengineering Strategies in Cancer Diagnosis and Therapy', Clinical and Translational Oncology, 25(1), pp. 78-90.
Vancouver	Ghafelehbashi R, Farshbafnadi M, Aghdam NS, Amiri S, Salehi M, Razi S. Nanoimmunoengineering Strategies in Cancer Diagnosis and Therapy. Clinical and Translational Oncology. 2023;25(1):78-90.
BibTex	@article{ author = {Ghafelehbashi R and Farshbafnadi M and Aghdam NS and Amiri S and Salehi M and Razi S}, title = {Nanoimmunoengineering Strategies in Cancer Diagnosis and Therapy}, journal = {Clinical and Translational Oncology}, volume = {25}, number = {1}, pages = {78-90}, year = {2023} }
RIS	TY - JOUR AU - Ghafelehbashi R AU - Farshbafnadi M AU - Aghdam NS AU - Amiri S AU - Salehi M AU - Razi S TI - Nanoimmunoengineering Strategies in Cancer Diagnosis and Therapy JO - Clinical and Translational Oncology VL - 25 IS - 1 SP - 78 EP - 90 PY - 2023 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract